May 7, 2024 | Press Releases
OVERLAND PARK, Kan.—(BUSINESS WIRE)—Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO), today announced the appointment of Sheldon Preskorn, M.D., as its Senior Vice President of Neuroscience. Dr. Preskorn is a world-renowned...
Mar 13, 2024 | Press Releases
OVERLAND PARK, Kan.—(BUSINESS WIRE)—Dr. Vince Clinical Research (DVCR), a contract research organization specializing in early phase trials, announced the first dosing in a Phase II multi-center trial of SPN-820 in adults with major depressive disorder (MDD). DVCR is...
Dec 12, 2023 | Press Releases
OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), a full-service Phase I-II contract research organization (CRO) announced a new solution to conduct renal and hepatic impairment studies. The solution leverages trusted relationships...
Sep 7, 2023 | Press Releases
Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom study. This study is taking place in...
Aug 29, 2023 | Press Releases
Strategic collaboration amplifies accessibility to Clario’s Early Precision QT (EPQT) methodology, enabling biopharmaceutical firms to secure more accurate and cost-efficient cardiac safety data in early clinical development stages. Meticulous multi-stage evaluation...
Aug 2, 2023 | Press Releases
OVERLAND PARK, Kan.; August 2, 2023 – Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending dose study...
Recent Comments